FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361954107> ?p ?o ?g. }

• W4361954107 abstract "<div>AbstractPurpose:<p>Selinexor is an oral selective inhibitor of exportin-1 (XPO1) with efficacy in various solid and hematologic tumors. We assessed intratumoral penetration, safety, and efficacy of selinexor monotherapy for recurrent glioblastoma.</p>Patients and Methods:<p>Seventy-six adults with Karnofsky Performance Status ≥ 60 were enrolled. Patients undergoing cytoreductive surgery received up to three selinexor doses (twice weekly) preoperatively (Arm A; <i>n</i> = 8 patients). Patients not undergoing surgery received 50 mg/m² (Arm B, <i>n</i> = 24), or 60 mg (Arm C, <i>n</i> = 14) twice weekly, or 80 mg once weekly (Arm D; <i>n</i> = 30). Primary endpoint was 6-month progression-free survival rate (PFS6).</p>Results:<p>Median selinexor concentrations in resected tumors from patients receiving presurgical selinexor was 105.4 nmol/L (range 39.7–291 nmol/L). In Arms B, C, and D, respectively, the PFS6 was 10% [95% confidence interval (CI), 2.79–35.9], 7.7% (95% CI, 1.17–50.6), and 17% (95% CI, 7.78–38.3). Measurable reduction in tumor size was observed in 19 (28%) and RANO-response rate overall was 8.8% [Arm B, 8.3% (95% CI, 1.0–27.0); C: 7.7% (95% CI, 0.2–36.0); D: 10% (95% CI, 2.1–26.5)], with one complete and two durable partial responses in Arm D. Serious adverse events (AEs) occurred in 26 (34%) patients; 1 (1.3%) was fatal. The most common treatment-related AEs were fatigue (61%), nausea (59%), decreased appetite (43%), and thrombocytopenia (43%), and were manageable by supportive care and dose modification. Molecular studies identified a signature predictive of response (AUC = 0.88).</p>Conclusions:<p>At 80 mg weekly, single-agent selinexor induced responses and clinically relevant PFS6 with manageable side effects requiring dose reductions. Ongoing trials are evaluating safety and efficacy of selinexor in combination with other therapies for newly diagnosed or recurrent glioblastoma.</p></div>" @default.
• W4361954107 created "2023-04-05" @default.
• W4361954107 creator A5001268928 @default.
• W4361954107 creator A5010891460 @default.
• W4361954107 creator A5014280061 @default.
• W4361954107 creator A5015187893 @default.
• W4361954107 creator A5017756904 @default.
• W4361954107 creator A5021656597 @default.
• W4361954107 creator A5038798689 @default.
• W4361954107 creator A5039640673 @default.
• W4361954107 creator A5044222252 @default.
• W4361954107 creator A5046245448 @default.
• W4361954107 creator A5051352882 @default.
• W4361954107 creator A5051363890 @default.
• W4361954107 creator A5057755017 @default.
• W4361954107 creator A5059797681 @default.
• W4361954107 creator A5062971193 @default.
• W4361954107 creator A5070373312 @default.
• W4361954107 creator A5071420169 @default.
• W4361954107 creator A5075810115 @default.
• W4361954107 date "2023-03-31" @default.
• W4361954107 modified "2023-10-17" @default.
• W4361954107 title "Data from A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma" @default.
• W4361954107 doi "https://doi.org/10.1158/1078-0432.c.6530990.v1" @default.
• W4361954107 hasPublicationYear "2023" @default.
• W4361954107 type Work @default.
• W4361954107 citedByCount "0" @default.
• W4361954107 crossrefType "posted-content" @default.
• W4361954107 hasAuthorship W4361954107A5001268928 @default.
• W4361954107 hasAuthorship W4361954107A5010891460 @default.
• W4361954107 hasAuthorship W4361954107A5014280061 @default.
• W4361954107 hasAuthorship W4361954107A5015187893 @default.
• W4361954107 hasAuthorship W4361954107A5017756904 @default.
• W4361954107 hasAuthorship W4361954107A5021656597 @default.
• W4361954107 hasAuthorship W4361954107A5038798689 @default.
• W4361954107 hasAuthorship W4361954107A5039640673 @default.
• W4361954107 hasAuthorship W4361954107A5044222252 @default.
• W4361954107 hasAuthorship W4361954107A5046245448 @default.
• W4361954107 hasAuthorship W4361954107A5051352882 @default.
• W4361954107 hasAuthorship W4361954107A5051363890 @default.
• W4361954107 hasAuthorship W4361954107A5057755017 @default.
• W4361954107 hasAuthorship W4361954107A5059797681 @default.
• W4361954107 hasAuthorship W4361954107A5062971193 @default.
• W4361954107 hasAuthorship W4361954107A5070373312 @default.
• W4361954107 hasAuthorship W4361954107A5071420169 @default.
• W4361954107 hasAuthorship W4361954107A5075810115 @default.
• W4361954107 hasBestOaLocation W43619541072 @default.
• W4361954107 hasConcept C126322002 @default.
• W4361954107 hasConcept C141071460 @default.
• W4361954107 hasConcept C2776194525 @default.
• W4361954107 hasConcept C44249647 @default.
• W4361954107 hasConcept C502942594 @default.
• W4361954107 hasConcept C71924100 @default.
• W4361954107 hasConcept C90924648 @default.
• W4361954107 hasConceptScore W4361954107C126322002 @default.
• W4361954107 hasConceptScore W4361954107C141071460 @default.
• W4361954107 hasConceptScore W4361954107C2776194525 @default.
• W4361954107 hasConceptScore W4361954107C44249647 @default.
• W4361954107 hasConceptScore W4361954107C502942594 @default.
• W4361954107 hasConceptScore W4361954107C71924100 @default.
• W4361954107 hasConceptScore W4361954107C90924648 @default.
• W4361954107 hasLocation W43619541071 @default.
• W4361954107 hasLocation W43619541072 @default.
• W4361954107 hasOpenAccess W4361954107 @default.
• W4361954107 hasPrimaryLocation W43619541071 @default.
• W4361954107 hasRelatedWork W2002120878 @default.
• W4361954107 hasRelatedWork W2003938723 @default.
• W4361954107 hasRelatedWork W2047967234 @default.
• W4361954107 hasRelatedWork W2118496982 @default.
• W4361954107 hasRelatedWork W2364998975 @default.
• W4361954107 hasRelatedWork W2369162477 @default.
• W4361954107 hasRelatedWork W2439875401 @default.
• W4361954107 hasRelatedWork W4238867864 @default.
• W4361954107 hasRelatedWork W2519357708 @default.
• W4361954107 hasRelatedWork W2525756941 @default.
• W4361954107 isParatext "false" @default.
• W4361954107 isRetracted "false" @default.
• W4361954107 workType "article" @default.